Bluejay Diagnostics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bluejay Diagnostics, Inc. (BJDX) on August 24, 2023, with the earliest event date of August 24, 2023. The filing details a registered direct offering and a concurrent private placement of equity securities. The transaction closed on August 28, 2023.
Key Financial Metrics and Transaction Details
The filing reports the following specific financial terms regarding the capital raise:
- Gross Proceeds: Approximately $1.59 million from the combined Offering and Private Placement, before deducting fees and expenses.
- Common Stock Issued: 216,000 shares at a purchase price of $7.365 per share.
- Warrants Issued to Investors: 216,000 unregistered warrants (one per share) with an exercise price of $7.24 per share, exercisable immediately and expiring in five years.
- Placement Agent Fees:
- Cash fee: 7.0% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Non-accountable expenses: $45,000.
- Clearing fees: $15,950.
- Placement Agent Warrants: 15,120 warrants (7.0% of shares sold) with an exercise price of $9.2063 per share.
The filing does not provide data on revenue, profit, cash flow, operating margins, existing debt, or liquidity positions as of the reporting date.
Material Changes
The primary material change is the increase in outstanding common stock and the creation of new warrant obligations resulting from the August 28, 2023 closing. The filing does not provide comparative financial data against prior periods.
Outlook, Risks, and Covenants
Lock-Up Provisions:
- The Company is prohibited from issuing or announcing the issuance of Common Stock or convertible securities for 15 days following the closing date.
- The Company is prohibited from entering into Variable Rate Transactions for one year following the closing date.
Fundamental Transactions: In the event of a Fundamental Transaction, the successor entity assumes all obligations. Warrant holders may be entitled to consideration equal to the Black-Scholes value of their warrants upon consummation of such a transaction.
Regulatory Status: The Company is an emerging growth company. The Common Stock was sold pursuant to a shelf registration statement (Form S-3), while the Warrants were sold under Section 4(a)(2) and Rule 506 exemptions.
Key Facts for Investor Verification
- Verify the net proceeds after deducting the 7.0% placement fee, 1.0% management fee, and fixed expenses ($60,950 total fixed costs).
- Confirm the dilution impact of the 216,000 new shares and the potential dilution from 231,120 total warrants issued (investor and placement agent).
- Review the Company's current cash balance and burn rate to assess the runway provided by the $1.59 million gross raise.
- Check for any subsequent filings regarding the use of proceeds or changes in the Company's capital structure within the 15-day lock-up period.